At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 119 enrolled
Drug / intervention
Secukinumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 28-week, Randomized, Double-blind, Active Controlled, Multicenter Study to Evaluate the Efficacy of Subcutaneously Administered Secukinumab Compared to Ustekinumab in Adult Patients With Psoriatic Arthritis and Failure of TNFα- Inhibitor Treatment (AgAIN)
In Brief
A Phase 3 clinical trial evaluating Secukinumab and Ustekinumab for Psoriatic Arthritis. Completed, enrolled 119 participants across 28 sites.
Detailed Summary
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionOct 2024
TodayJul 2026
First PostedNov 17, 2020
Enrollment StartDec 21, 2020
Primary CompletionOct 22, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.6 years ago
Interventions
Secukinumabbiological
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Ustekinumabbiological
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio